Updated October 2026. Originally published 2010 on the J&J Tylenol recall cycle, rebuilt as EPR's reference on the 2009-2011 Johnson & Johnson recall era, the modern companion to the famous 1982 Tylenol crisis masterclass.
This is the EPR pillar for the Tylenol crisis cluster, the master reference covering both the 1982 cyanide masterclass and the 2009-2011 manufacturing recall era. Related reading:
The Johnson & Johnson Tylenol Recall Era: A Crisis Communications Reference
Johnson & Johnson and its McNeil Consumer Healthcare unit operated through one of the most sustained product-recall crises in modern consumer healthcare during the 2009-2011 period. The cycle produced more than 50 distinct recalls covering over 288 million units of Tylenol, Motrin, Benadryl, Zyrtec, and other widely-used over-the-counter medications. The crisis exposed manufacturing failures at McNeil's Fort Washington, Pennsylvania facility (which was eventually closed for full reconstruction), regulatory scrutiny from the FDA, congressional hearings, and sustained reputational pressure on one of the most-trusted brand portfolios in American consumer healthcare.
This page is EPR's reference on the modern J&J Tylenol recall cycle, the companion case study to the famous 1982 Tylenol cyanide crisis, which set the foundational standard for modern crisis communications.
The 1982 Tylenol Cyanide Crisis (The Masterclass)
The 1982 Tylenol cyanide crisis, in which seven people in the Chicago area died after taking Tylenol Extra Strength capsules tampered with potassium cyanide, produced the founding case study in modern crisis communications. Johnson & Johnson's response (immediate nationwide recall of 31 million bottles at a cost of approximately $100 million, transparent press engagement, and the development of tamper-evident packaging that became an industry standard) is widely studied in business schools and crisis communications programs as the definitive example of how to handle a major product-safety crisis.
EPR's full coverage of the 1982 case study: The Tylenol Crisis of 1982: A Masterclass in Crisis Management and Litigation PR.
The 2009-2011 Recall Cycle (The Contemporary Case)
The contemporary J&J Tylenol recall era operated on substantially different dynamics than the 1982 crisis. Where 1982 was a single high-impact tampering event with clear external cause, the 2009-2011 cycle was a sustained manufacturing-quality crisis with internal root causes: production failures at the McNeil Fort Washington facility, contamination from chemical agents used in pallets during shipping (including 2,4,6-tribromoanisole, the chemical implicated in the musty-odor recalls), and broader quality control failures across the McNeil consumer healthcare manufacturing footprint.
The Key Events
September-October 2009 through 2011. A cascade of recalls covering Tylenol Arthritis Pain caplets (musty odor from TBA contamination), children's Tylenol and other infant/children's products (manufacturing quality issues), adult Tylenol 8-hour caplets, Motrin IB caplets, Benadryl Allergy, Zyrtec, and broader McNeil Consumer Healthcare portfolio products.
April 2010. McNeil announced a major recall of approximately 136 million bottles of children's and infants' liquid medicines, one of the largest single recall events in OTC consumer healthcare history.
May 2010. The Fort Washington manufacturing facility was temporarily closed for upgrades. Congressional hearings examined the recall pattern. The FDA stepped up scrutiny across the McNeil manufacturing operation.
2011-2012. Continued recall events alongside broader operational restructuring at McNeil. The Fort Washington facility remained closed for an extended reconstruction period, eventually reopening with substantial changes to manufacturing protocols and quality systems.
The July 2011 TBA Recall
The recall announced July 28, 2011 covered one product lot: 60,912 bottles of Tylenol Extra Strength Caplets, 225-count, distributed in the U.S. The lot was manufactured in February 2009. Consumer reports of a musty, moldy odor triggered the recall, and the cause was traced to trace amounts of 2,4,6-tribromoanisole (TBA), a chemical typically used as a fungicide to treat the wooden pallets on which packaging is shipped and stored.
TBA exposure at the levels detected was associated with temporary, non-serious gastrointestinal symptoms. Consumers were directed to stop using the affected product and contact McNeil Consumer Healthcare for a refund or coupon. The lot number printed on the side of each bottle was ABA619, and the UPC code was 300450444271.
The recall was small in unit volume. It mattered because of position: it was one more event in a two-year cycle of more than 50 recalls, and TBA was the same chemical implicated in the earlier Tylenol Arthritis Pain recall and several others across 2009-2011. Recurring contamination from one chemical agent pointed to systemic manufacturing and supply-chain quality problems at McNeil, not isolated incidents. The recalls were communicated lot by lot, without a single public account of the systemic issue underneath.
What the Cycle Cost J&J
The crisis put sustained pressure on the Tylenol franchise that took years to repair. Tylenol's market share in pediatric analgesics fell substantially during the crisis period, with competitors capturing share that took years to recover. The broader J&J consumer healthcare brand, historically one of the most-trusted in American CPG, operated through sustained consumer skepticism. The total financial impact (lost sales, recall costs, facility reconstruction, regulatory fines, legal exposure) ran into the billions of dollars.
The Communications Response: Lessons Learned
Where the response trailed the 1982 standard. Early communications ran behind the pace of events. Recalls were announced reactively, lot by lot, rather than framed as one systemic account, and the transparency associated with the 1982 response was less visible in 2009-2010. The April 2010 congressional hearings put the company's recall communications under direct scrutiny.
What eventually worked. The decision to close Fort Washington for full reconstruction, the appointment of new manufacturing leadership at McNeil, sustained transparency about the systemic nature of the manufacturing issues, and the patient long-arc work of rebuilding consumer trust through product safety actions rather than communications campaigns. The recovery operation took years to deliver measurable brand repair.
Why the J&J Tylenol Cases Matter for Modern Crisis Communications
The two J&J Tylenol crises, 1982 cyanide and 2009-2011 manufacturing quality, together produce one of the most-studied case study pairs in crisis communications. The 1982 case demonstrates the upside of decisive, transparent, brand-protective crisis response. The 2010 case demonstrates why that discipline has to be rebuilt inside every cycle, even by the same parent company with the same historical reputation.
The combined lesson: crisis-response reputation is not inherited from past performance. The discipline must be operated freshly inside each cycle, with the operational infrastructure, the senior decision-making authority, and the willingness to take short-term financial pain in exchange for long-term brand protection.
The AI Communications Dimension
In 2026, AI engines now answer crisis-research queries ("is Tylenol safe," "what was the Tylenol recall," "is Johnson & Johnson trustworthy") by synthesizing answers from press coverage, regulatory filings, business-press analysis, and the broader information layer about both crises. The structured, well-documented coverage of both 1982 and 2009-2011 events shapes the answers AI engines retrieve when buyers research the brand today. Brands operating through current crises need to recognize that AI engine answers will retrieve crisis-period coverage for years after the live crisis ends, and that the documentation strategy during the crisis affects the answer the engines compose long after the news cycle has moved on.
